$294 Million

Agios Pharmaceuticals

Follow-on Offering

Bookrunner, November 2019

Agios Pharmaceuticals
Agios currently expects to use the net proceeds from the follow-on offering to fund ongoing research, clinical development and commercial efforts, including preparation for the anticipated regulatory approval and commercial launch of TIBSOVO in relapsed or refractory AML in Europe; regulatory filing, approval and commercial launch of TIBSOVO in second line or later cholangiocarcinoma in the U.S.; enrollment in the Company’s Phase 3 AGILE trial with ivosidenib in combination with azacitidine in frontline AML patients ineligible for chemotherapy; enrollment in HO150/AMLSG29, an intergroup sponsored Phase 3 trial combining ivosidenib or enasidenib and standard induction and consolidation chemotherapy in frontline AML patients; enrollment in the Company’s Phase 1 trial of ivosidenib in myelodysplastic syndrome (MDS); initiation and enrollment of the Company’s Phase 3 INDIGO trial with vorasidenib in low grade (grade 2) glioma; completion and data readouts of the ACTIVATE and ACTIVATE-T pivotal trials and global launch preparation activities for mitapivat in adults with PK deficiency; completion and data readout of the Company’s Phase 2 trial of mitapivat in thalassemia; enrollment in two dose expansion arms of a Phase 1 trial of AG-270 in MTAP-deleted cancers, in a Phase 1 trial for AG-636 in lymphoma; IND-enabling activities and, if successful, a Phase 1 clinical trial for the next-generation PKR activator; Advancement of the Company’s late-stage preclinical pipeline; other ongoing and planned clinical trials and working capital and other general corporate purposes.